Last Day of Dealings on AIM

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Last Day of Dealings on AIM

Brighton, United Kingdom ‐ 12 August 2024 ‐ Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life‐threatening infections, reminds shareholders that the last day of trading in Destiny Pharma’s ordinary shares on AIM is today, 12 August 2024.

The cancellation of the admission of the Company’s ordinary shares to trading on AIM (the “Cancellation”) was originally announced on 15 July 2024 and was approved by shareholders at the general meeting held on 31 July 2024.

The Cancellation will become effective at 7:00 a.m. on 13 August 2024. Following Cancellation, the Company will reregister as a private company under the name Destiny Pharma Limited.

Matched Bargain Facility Arrangements
The Company’s ordinary shares will be admitted to trading on the JP Jenkins securities matching platform from 13 August 2024.

JP Jenkins provides a securities matching venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell shares on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).

Shareholders wishing to trade these securities can do so through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK regulated stockbroker.

The indicative pricing for the ordinary Shares (ISIN: GB00BDHSP575), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/destiny-pharma).

Following Cancellation, shareholders are encouraged to sign up to the Company’s email news alerts via the Destiny Pharma website to remain up to date with the Company’s developments.

Further details regarding the Cancellation and re‐registration are set out in the circular sent to shareholders dated 15 July 2024. A copy of the circular is available on the Company’s website www.destinypharma.com

Following Cancellation, Shore Capital will cease to act as nominated adviser and corporate broker to the Company.

For further information, please contact:

Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com

FTI Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
destinypharma@fticonsulting.com

Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090

About Destiny Pharma
Destiny Pharma is an innovative, clinical‐stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life‐threatening infections. The Company’s drug development pipeline includes two late‐stage assets XF‐73 Nasal gel, a proprietary drug targeting the prevention of post‐surgical staphylococcal hospital infections including MRSA and NTCD‐M3, a microbiome‐based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US.

For further information on the company, please visit www.destinypharma.com.